Alexion Pharmaceuticals Inc. (ALXN) Stock Quote

Detailed Quote for Alexion Pharmaceuticals Inc. (ALXN)

After Hours: $ 82.6487

-0.7963 (-0.95%)

Volume: 36.19 k

5:19 PM EST Feb 10, 2012

close 52 Week Information

52 Week High

February 10, 2012

Close: 83.88

52 Week Low

February 14, 2011

Close: 22.27

Today

Last Price
83.445

Change $
3.035

Change %
3.77%

Tick
N/A

Bid
N/A

Bid Size
0

Ask
N/A

Ask Size
0

Open
81.39

High
83.88

Low
81.07

Prev Close
80.41

Last Trade
2/10/12

Volume
2.1 m

52 Wk Hi
83.88

52 Wk Low
22.27

Market Cap
15.45 b

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
185,147,112

EPS (TTM)
0.80

PE Ratio
104.30

close Exchange Information Listed On Nasdaq Global Select (NGS) Exchange
NGS

News and Media for Alexion Pharmaceuticals Inc. (ALXN)

Sector News | Topic News

News for ALXN

Fri, Feb 10, 2012

10:00 AM

Alexion to Present at the Leerink Swann 2012 Global Healthcare Conference - Business Wire

Thu, Feb 09, 2012

6:30 AM

Alexion Reports Fourth Quarter and Full Year 2011 Results - Business Wire

Tue, Feb 07, 2012

10:15 AM

Alexion Completes Acquisition of Enobia Pharma Corp. - Business Wire

Mon, Jan 30, 2012

10:00 AM

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2011 Results on Thursday, February 9, 2012 - Business Wire

Tue, Jan 03, 2012

10:00 AM

Alexion to Present at the 30th Annual JP Morgan Healthcare Conference - Business Wire

Thu, Dec 29, 2011

5:01 PM

Capital régional et coopératif Desjardins sells its interest in Enobia Pharma - Canada Newswire

6:00 AM

Alexion to Host Conference Call This Morning to Discuss Company's Proposed Acquisition of Enobia Pharma Corp. - Business Wire

Wed, Dec 28, 2011

4:13 PM

Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP) - Business Wire

4:11 PM

Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP) - Business Wire

Mon, Dec 12, 2011

1:00 PM

New Data Confirm Hemolysis as Predictor of Thromboembolism and Early Death in Patients with PNH and Demonstrate Need To Test High-Risk Patients for PNH - Business Wire

Tue, Nov 29, 2011

7:16 AM

Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS) - Business Wire

Wed, Nov 23, 2011

10:00 AM

Alexion to Present at the 23rd Annual Piper Jaffray Health Care Conference - Business Wire

Tue, Oct 11, 2011

10:24 AM

Emerging companies in the diabetic treatment space rising - Accesswire

Mon, Sep 19, 2011

9:30 AM

Zacks' Voice of the People Highlights Opportunities with Advance Auto Parts, Alexion Pharma and Solera Holdings - PR Newswire

More News for ALXN >>

Tags for Alexion Pharmaceuticals Inc.

Research stocks or mutual funds related to Alexion Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to ALXN. The keywords below have been associated to ALXN by either user submission or electronic means.

typhoid vaccine biotechnology company pharmaceuticals research eculizumab alexion pharmaceuticals biotech conference pharmaceutical market pharmaceuticals companies generic pharmaceutical pharmaceuticals logistics pharmaceuticals careers job in pharmaceuticals mgi pharma hepatitis vaccination europe pharmaceuticals pharmaceutical research and development mmr vaccine rabies vaccine dupont pharmaceuticals tetanus vaccine pharmaceuticals germany vaccination schedule chickenpox vaccine hepatitis vaccine tetanus shots novartis pharmaceuticals pharmaceutical cro pharma companies pharmaceutical sales abo pharmaceuticals travel vaccinations pharmaceutical development vaccination pharmaceutical magazine meningitis vaccination biotech pnh disease bcg vaccine worldwide clinical trials Drugs pharma clinical trials Hemoglobinuria pharmaceutical manufacturing software childhood vaccinations pharmaceutical manufacturing career in pharmaceuticals contract pharmaceutical pharmaceutical events pharmaceutical industry vaccine